Molbio shares surge on Jefferies' bullish stance on innovation strategy

Shares of Molbio Diagnostics gained 9 per cent following Jefferies' initiation of coverage with a positive stance on the company's innovation-focused approach. The brokerage has designated Molbio as a 'high-conviction pick', signalling strong confidence in the company's growth trajectory and strategic direction.

Jefferies has assigned a target price of ₹1,600 per share, which represents an upside of approximately 27 per cent from the stock's last closing price of ₹1,255.60. The target price reflects the brokerage's belief in the company's ability to leverage its innovation capabilities to capture market opportunities and expand its footprint in the diagnostics sector.

Molbio has established itself as a player in the molecular diagnostics space, with a focus on developing advanced testing solutions. The company's emphasis on research and development, coupled with its technological innovations, has attracted institutional attention as investors seek exposure to the growing healthcare diagnostics market in India.

The positive outlook from Jefferies aligns with broader industry trends, as demand for diagnostic solutions continues to rise across India. The brokerage's assessment suggests that Molbio's strategy of prioritising innovation could position it well to capitalise on evolving market demands and healthcare spending patterns in the region.